Cocrystal Pharma Inc (OTCMKTS:COCP)’s share price was down 0.9% during mid-day trading on Monday . The company traded as low as $2.30 and last traded at $2.32, approximately 1,636 shares traded hands during mid-day trading. A decline of 91% from the average daily volume of 18,268 shares. The stock had previously closed at $2.34.
The business’s 50 day moving average is $2.27 and its 200-day moving average is $2.53.
A number of institutional investors have recently added to or reduced their stakes in the stock. Wasatch Advisors Inc. grew its stake in Cocrystal Pharma by 5.4% in the 2nd quarter. Wasatch Advisors Inc. now owns 1,152,731 shares of the company’s stock valued at $2,709,000 after acquiring an additional 59,235 shares during the period. Vanguard Group Inc. grew its stake in Cocrystal Pharma by 4.4% in the 2nd quarter. Vanguard Group Inc. now owns 360,364 shares of the company’s stock valued at $847,000 after acquiring an additional 15,336 shares during the period. BlackRock Inc. boosted its stake in Cocrystal Pharma by 15.3% during the 2nd quarter. BlackRock Inc. now owns 35,323 shares of the company’s stock worth $83,000 after purchasing an additional 4,685 shares during the last quarter. Finally, Dimensional Fund Advisors LP boosted its stake in Cocrystal Pharma by 206.9% during the 4th quarter. Dimensional Fund Advisors LP now owns 33,309 shares of the company’s stock worth $120,000 after purchasing an additional 22,457 shares during the last quarter.
Cocrystal Pharma, Inc, formerly Biozone Pharmaceuticals, Inc, is engaged in developing medicines for use in the treatment of human viral diseases. The Company develops technologies and approaches to create antiviral drug candidates. The Company is developing antiviral therapeutics that inhibit the replication function of a virus, including the ribonucleic acid (RNA)-dependent RNA polymerase enzyme, the helicase enzyme and the NS5A protein of hepatitis C virus (HCV), and the polymerase enzymes of influenza virus and norovirus.
Read More: How Do You Calculate Return on Equity (ROE)?
Receive News & Ratings for Cocrystal Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cocrystal Pharma and related companies with MarketBeat.com's FREE daily email newsletter.